Verrica Pharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Verrica Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Verrica Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$20.7M, a 13.4% increase year-over-year.
  • Verrica Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$77.6M, a 59% decline year-over-year.
  • Verrica Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$65.8M, a 209% decline from 2022.
  • Verrica Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$21.3M, a 31.1% increase from 2021.
  • Verrica Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$30.9M, a 23.1% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$77.6M -$20.7M +$3.21M +13.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$80.9M -$15.2M -$3.59M -30.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$77.3M -$18.6M -$11.5M -162% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$65.8M -$23.1M -$16.9M -272% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$48.8M -$23.9M -$25.4M -1752% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$23.5M -$11.6M -$2.5M -27.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$21M -$7.09M +$321K +4.33% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$21.3M -$6.21M +$2.26M +26.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$23.6M $1.45M +$13.2M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$36.8M -$9.12M +$1.61M +15% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$38.4M -$7.41M -$7.47M -12450% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$30.9M -$8.47M +$3.56M +29.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$34.5M -$11.8M -$2.13M -22.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$32.3M -$10.7M -$2.1M -24.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$30.2M $60K +$9.94M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$40.2M -$12M -$4.04M -50.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$36.1M -$9.64M -$3.09M -47.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$33M -$8.63M -$1.11M -14.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$31.9M -$9.88M -$1.85M -23.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$30.1M -$7.99M +$198K +2.42% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-13
Q3 2019 -$30.3M -$6.54M -$211K -3.33% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$30.1M -$7.52M -$2.05M -37.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$28M -$8.03M -$6.14M -325% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$21.9M -$8.19M -$6.75M -471% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$15.1M -$6.33M -$4.97M -366% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$10.2M -$5.47M -$4.38M -400% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 -$5.78M -$1.89M -$1.32M -231% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$4.46M -$1.43M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$1.36M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$1.1M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$570K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.